3 Uranium Stocks to Buy as Nuclear Heats Before the End of July
The article highlights three uranium-related stocks ahead of a July Section 232 status report that could tighten domestic-sourcing rules. It cites CCJ Q1 FY2026 results and 2026 delivery guidance of 29-32 million lb at $85-$89/lb, UEC’s zero-debt balance sheet and unhedged pricing, and LEU’s Q1 FY2026 EPS beat and raised 2026 revenue guidance of $450-$500 million.
How this was made
The 30-second read
Why it matters
It argues that domestic-sourcing rules would favor US uranium producers and US-owned enrichment, using each company’s recent financial/operational datapoints and a near-term catalyst calendar (Section 232 timing and CCJ Q2 on July 31).
Market read
Traders are given a policy-timing trade setup across mining and enrichment, but the article does not disclose a new policy outcome, only expectations and company-specific recent results.
What to watch
UEC’s Q3 revenue plan (zero sales) and LEU’s execution and DOE funding/appropriations risk could dominate stock moves if policy language is weaker than expected or costs continue rising.
Background
The piece frames July as an inflection point for the uranium supply chain, centered on a Section 232 status report due this month and ongoing nuclear demand growth.
Ticker impact
Cameco is cited with Q1 FY2026 uranium sales volumes up 13% to 7.8M pounds and 2026 guidance at $85 to $89/lb.
Near-term upside bias into month-end around Q2 results (July 31) and any Section 232 update, with volatility likely lower than peers.
The article provides specific earnings and guidance datapoints for CCJ plus a defined next catalyst (July 31 Q2), but it is still a promotional-style basket piece rather than a single fresh disclosure.
Uranium Energy is described as unhedged, with Q2 FY2026 sales at $101/lb and a zero-debt balance sheet, plus a Section 232 beneficiary framing.
Higher probability of sharp re-rating around the July Section 232 status report, but with downside risk from Q3 revenue absence and rising costs.
The text includes concrete operational and balance-sheet details (zero debt, liquid assets, Q2 realized price, Q3 zero sales) and a specific policy timing window, but it does not present a newly released policy decision.
Centrus Energy is positioned as the only US-owned uranium enricher, citing Q1 FY2026 EPS of $1.05 vs 27 cents consensus and raised 2026 revenue guidance to $450M to $500M.
Potential upside into the July policy window, with follow-through tied to DOE task order execution and centrifuge build progress.
The article provides multiple specific financial and contract/backlog figures for LEU and a defined policy catalyst, but it remains an editorial “buy” list rather than a new contract award or policy ruling.
Market effects
Reinforces a uranium complex trade that links policy (Section 232) to realized pricing, contracting, and enrichment/HALEU supply constraints.
US-focused domestic sourcing narrative could shift relative attractiveness toward US miners and US-owned enrichment capacity.
Highlights global nuclear expansion and AI-linked power demand as the demand backdrop supporting long-duration uranium contracting.
Counterpoint
Even with a favorable Section 232 report, actual import restrictions and enforcement timing may lag, limiting near-term re-rating versus the article’s urgency.
Key entities
- policySection 232 uranium status report
A status report due in July that could impose domestic-sourcing rules and affect uranium import dynamics.
- public_companyCameco
US-listed uranium miner with Q1 FY2026 sales volume and 2026 delivery price guidance cited, plus July 31 Q2 results as a near-term catalyst.
- public_companyUranium Energy
US domestic ISR producer described as unhedged with zero debt and Q2 realized pricing cited, positioned as a direct Section 232 beneficiary.
- public_companyCentrus Energy
US-owned uranium enricher described as the HALEU play, with Q1 EPS beat and raised 2026 revenue guidance cited.
